Cargando…

Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer

The platelet-derived growth factor (PDGF) family, a complex and imperative group of proangiogenic factors, acts as strong cell growth chemokines and is essential for the progression of malignancy in humans. In the present study, it was observed that aberrant PDGFB expression is associated with survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sangmin, You, Daeun, Jeong, Yisun, Yoon, Sun Young, Kim, Sung A, Lee, Jeong Eon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905523/ https://www.ncbi.nlm.nih.gov/pubmed/33732370 http://dx.doi.org/10.3892/ol.2021.12555

Ejemplares similares

Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
por: You, Daeun, et al.
Publicado: (2017)

Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells
por: Kim, Sangmin, et al.
Publicado: (2023)

Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
por: You, Daeun, et al.
Publicado: (2023)

Celastrol attenuates the inflammatory response by inhibiting IL-1β expression in triple-negative breast cancer cells
por: You, Daeun, et al.
Publicado: (2021)

Entelon(®) (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells
por: You, Daeun, et al.
Publicado: (2021)

Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells
por: Jeong, Yisun, et al.
Publicado: (2018)

Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase
por: Han, Jeonghun, et al.
Publicado: (2019)

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
por: Han, Wonshik, et al.
Publicado: (2006)

SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells
por: Jin, Ming Li, et al.
Publicado: (2022)

miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer
por: Kim, Ye Sol, et al.
Publicado: (2016)

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
por: Chang, Bo Yoon, et al.
Publicado: (2011)

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
por: Kim, Yun Gyoung, et al.
Publicado: (2019)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
por: Gao, Pin, et al.
Publicado: (2018)

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
por: CHEN, MING, et al.
Publicado: (2013)

Identification and Analysis of Estrogen Receptor α Promoting Tamoxifen Resistance-Related lncRNAs
por: Zhang, Xiulei, et al.
Publicado: (2020)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
por: Lee, Dahae, et al.
Publicado: (2021)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
por: Yang, Li-Heng, et al.
Publicado: (2012)

miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
por: HE, YUE-JUN, et al.
Publicado: (2013)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

Prognostic significance of autophagy related genes in estrogen receptor positive tamoxifen treated breast cancer
por: Mishra, Alok, et al.
Publicado: (2020)

Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer
por: Boustan, Arad, et al.
Publicado: (2021)

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
por: Barros, Milton J., et al.
Publicado: (2023)

Estrogen Receptor Expression and Estrogen Receptor‐independent Cytotoxic Effects of Tamoxifen on Malignant Rhabdoid Tumor Cells in vitro
por: Koshida, Shigeki, et al.
Publicado: (2002)

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel, Nelson, et al.
Publicado: (2017)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kt575qrmoapht5nki3fjj1ifo8